InSilicoTrials is thrilled to announce the publication of “?????? ???d ?????????? ???????? – Best practices for the use of computational modelling & simulation in the regulatory process of biomedical products ” a crucial document guiding the use of simulation data
At the Brain Innovation Days held in Brussels on October 26-27, 2023, organised by the European Brain Council, representatives from the BRAINTEASER project and from other pertinent initiatives gathered for a roundtable discussion. The focus was on promoting collaboration among various EU
iDPP@CLEF [1] is an open evaluation challenge to assess the performance of Artificial Intelligence (AI) algorithms to predict the progression of Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). iDPP stands for Intelligent Disease Progression Prediction and it is a series of events, organised by the BRAINTEASER project, co-located with the Conference
Axoltis Pharma is at the forefront of developing treatments for neurodegenerative diseases, with their phase 1b clinical trial of NX210c marking a notable achievement in the field. This peptide drug candidate has shown promising results following a successful phase 1a
The life sciences sector is beginning to experience the transformative effects of AI, with numerous applications offering clinical, operational, and medical advantages. Unlike other industries, life sciences face the unique challenge of safeguarding patient safety and privacy. This has led
Mamede de Carvalho, a renowned neurologist and the head of the Amyotrophic Lateral Sclerosis (ALS) Clinic at Centro Hospitalar Universitário Lisboa Norte (CHULN), situated at the prestigious Hospital de Santa Maria, recently unveiled the exciting BRAINTEASER project during an exclusive
Welcome back to InSilicoTrials’ Talks! We’re excited to launch our IST Customer Testimonials’ initiative, a series dedicated to hearing directly from our clients. Today, we feature Yann Godfrin, CEO of Axoltis Pharma, who joined us for an insightful in silico
InSilicoTrials has collaborated effectively with Biofarma Group to harness the potential of in silico technology for clinical research. In this collaboration, InSilicoTrials utilized its expertise in computational modeling to analyze and reinterpret the clinical trial data of Epatrex, Biofarma Group’s
Mamede de Carvalho, a renowned neurologist and the head of the Amyotrophic Lateral Sclerosis (ALS) Clinic at Centro Hospitalar Universitário Lisboa Norte (CHULN), situated at the prestigious Hospital de Santa Maria, recently unveiled the exciting BRAINTEASER project during an exclusive
Cutting-edge EU-funded project METASTRA unites an interdisciplinary team of experts to spearhead a transformative approach to revolutionize fracture risk assessment and personalized treatment for cancer patients with vertebral metastases. A groundbreaking initiative, METASTRA is set to transform the way clinicians
Each year, the BRAINTEASER project organizes an open evaluation challenge, called iDPP@CLEF (Intelligent Disease Progression Prediction), to involve research groups from academia and industry in the assessment of the performance of their AI algorithms to predict the progression of ALS
In Silico Trials, the use of computational modelling & simulation in the development and regulatory assessments of biomedical products is an emerging practice in the biomedical industry. While the first technical standards, such as the ASME VV-40:2018, are appearing, there